Exclusive: Germany wants to buy Sputnik COVID vaccine if approved by EU, source says
Reuters
Published Apr 07, 2021 04:05PM ET
Updated Apr 07, 2021 04:45PM ET
BERLIN (Reuters) - Germany is about to start bilateral negotiations with Russia to obtain its Sputnik V COVID-19 vaccine, a source told Reuters on Wednesday, adding that any final agreement depended on Russia providing key data to the European Medicines Agency (EMA).
The European Commission told health ministers of EU member states on Wednesday that Brussels was not planning to start talks with Russia on a preliminary contract for Sputnik V as it did with other vaccine providers, a person with knowledge of the matter told Reuters on condition of anonymity.
That is why German Health Minister Jens Spahn announced during the virtual meeting that Germany would start preliminary negotiations with Russia on a bilateral agreement to secure the vaccine, the source added.
In the preliminary talks, Germany first wants to determine which quantities Russia can deliver and when, the source said.
In any case, Germany will only buy the Russian vaccine once it has been approved by EMA and for this it is paramount that Russia provides the necessary data, the source added.
Earlier on Wednesday, the premier of Bavaria said the German region will buy 2.5 million doses of the Sputnik vaccine if it is approved by EMA.
Markus Soeder, premier of the wealthy southern German state, said the purchase would take place in July.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.